-- For the industry, the next step in antibody therapeutics is more efficient and more precise immune regulation. Creative Biolabs offers pharmaceutical companies and research institutions comprehensive solutions with strong translational value.
ADCC-Enhanced Antibodies: Strengthening Immune Clearance
Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the key effector mechanisms of monoclonal antibodies. However, the natural ADCC activity of antibodies is often limited. Creative Biolabs has developed a series of ADCC-enhanced biosimilars and biobetters. These molecules improve Fc–Fcγ receptor binding efficiency, thereby recruiting immune effector cells more effectively and enhancing cytotoxic responses. This technology has been successfully applied to multiple client antibodies targeting tumor and immune-related antigens, demonstrating significant potential in their early-stage research and drug development programs.
Fc-Silent Antibodies: Minimizing Immune Side Effects
At the same time, Fc-silent antibodies are attracting increasing attention across the field. In certain therapeutic contexts, the Fc effector function can lead to an over-activation of the immune system and cytokine release syndrome. By leveraging its well-established Fc engineering platform, Creative Biolabs can apply multiple molecular strategies to attenuate or completely abolish Fc interactions with Fcγ receptors and complement C1q, thereby producing truly Fc-silent antibodies. Current offerings include anti-ADDL Fc-silent antibodies, anti-amyloid beta Fc-silent antibodies, and anti-CD146 Fc-silent antibodies, all of which serve as valuable tools for research in neurodegenerative diseases and vascular-related conditions.
ADCC Cell Lines: Reliable Systems for Functional Evaluation
Besides the optimization of antibody efficacy, robust cell-based systems are critical for successful translational research. Creative Biolabs has established a collection of high-performance ADCC cell lines that provide stable and reproducible platforms for antibody activity assessment. These cell lines are widely used in candidate drug screening, functional validation, and quality control, ensuring a strong technical foundation for downstream development.
"We remain committed to providing global clients with antibody engineering solutions that combine innovation with practical applicability," said an antibody research expert at Creative Biolabs in a recent interview. "ADCC-enhanced antibodies and Fc-silent antibodies represent two important directions in therapeutic antibody development—one focusing on amplifying immune effects, and the other on carefully controlling immune activity. When paired with our in-house ADCC cell lines, clients are offered various customizable technical services, which ultimately accelerate the development of next-generation therapeutics."
About Creative Biolabs
Creative Biolabs has established a strong foundation for cross-disciplinary collaborative research covering diverse areas of diseases. The company will continue to invest in product and service pipeline expansion to translate more promising candidates into the flexible antibody development pathway.
Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://adcc.creative-biolabs.com/
Release ID: 89170621
Google
RSS